Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 103816-19-9 Chemical Structure| 103816-19-9

Structure of 103816-19-9

Chemical Structure| 103816-19-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 103816-19-9 ]

CAS No. :103816-19-9
Formula : C11H19ClN2O
M.W : 230.73
SMILES Code : O=C(Cl)N1CCC(N2CCCCC2)CC1
MDL No. :MFCD08445612
InChI Key :YDNSNQRKIINKPV-UHFFFAOYSA-N
Pubchem ID :9813375

Safety of [ 103816-19-9 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H312-H314-H332
Precautionary Statements:P280-P305+P351+P338-P310
Class:8
UN#:3261
Packing Group:

Computational Chemistry of [ 103816-19-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 69.77
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

23.55 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.74
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.22
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.53
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.88
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.64
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.0

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.54
Solubility 0.67 mg/ml ; 0.0029 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.35
Solubility 1.03 mg/ml ; 0.00447 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.67
Solubility 4.92 mg/ml ; 0.0213 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.13 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

2.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.95

Application In Synthesis of [ 103816-19-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 103816-19-9 ]

[ 103816-19-9 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 103816-19-9 ]
  • [ 86639-52-3 ]
  • [ 97682-44-5 ]
YieldReaction ConditionsOperation in experiment
95% With pyridine; acetamide; triethylamine; In dichloromethane; at 30 - 40℃; for 2h;Inert atmosphere;Product distribution / selectivity; Example 27-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (I)In a suitable vessel were charged 7-Ethyl-10-hydroxycamptothecin (20 g), methylene dichloride, acetamide (3 gm) and pyridine (60 ml) under nitrogen atmosphere.A solution of [1,4']bipiperidinyl-1'-carbonyl chloride (17.6 g), methylene dichloride and triethylamine (20 ml) was prepared and added to the above suspension and stirred at 30-40° C. for 2 hours.The solvent was distilled out under reduced pressure at 50° C. and hexane was added under stirring as an antisolvent to isolate crystalline compound.The crystalline compound was filtered, washed with hexane and dried under reduced pressure at 50° C.The yield was 28.4 g (95percent). HPLC Purity-99.9percent
95% With pyridine; In acetamide; dichloromethane; at 30 - 40℃; for 2h;Inert atmosphere;Product distribution / selectivity; Example 27-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy- camptothecin (I)In a suitable vessel were charged 7-Ethyl-10-hydroxycamptothecin (20 g), methylene dichloride, acetamide (3 gm) and pyridine (60ml) under nitrogen atmosphere.A solution of [1,4']bipiperidinyl-1'-carbonyl chloride (17.6 g), methylene dichloride and triethylamine (20ml) was prepared and added to the above suspension and stirred at 30-40 °C for 2 hours.The solvent was distilled out under reduced pressure at 50°C and hexane was added under stirring as an antisolvent to isolate crystalline compound.The crystalline compound was filtered, washed with hexane and dried under reduced pressure at 50 °C.The yield was 28.4 g (95 percent). HPLC Purity - 99.9percent
89% SN-38B-11 (1.22 g, 2.08 mmol, yield 89percent, enantiopurity 99.8percent ee) was obtained from SN-38 (0.91 g, 2 .32 mmol) synthesized in Example 9 by the reported procedure (Sawada, S.; Okajima, S.; Aiyama, R.; Nokata, K.; Furuta, T.; Yokokura, T.; Sugino, E.; Yamaguchi, K.; Miyasaka, T. Chem. Pharm. Bull. 1991, 39, 1446.).Chiral HPLC operation conditions Column: DAICEL CHIRALCEL OD-H, 0.46cmID.x.25cm (No.ODH0CE-AK031) Guard cartridge: DAICEL CHIRALCEL OD-H, 0.4cmIDxlcm Injection amount:10mug/10muL Temperature: constant temperature about 40°C Flow rate: 1mL/min Mobile phase: dimethylamine : hexane : ethanol mixture(1 : 250 : 250) Detect: 254nm
88% With 1,4-diaza-bicyclo[2.2.2]octane; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 35 - 40℃; for 0.5h;Product distribution / selectivity; EXAMPLE 1 A mixture of 25.02 g (0.0637 mol) 7-ethyl-10-hydroxycamptothecin, 18.72 g (0.07 mmol) of 4-piperidinopiperidinecarbonylchloride, 0.99 g (6.4 mmol) DABCO and 400 ml dichloromethane is treated with 18.93 g (0.146 mol) N,N-Diisopropylethylamine (DIEA) at 35 to 40° C. After 0.5 h complete conversion (>99percent), is observed. Subsequently, the organic layer is washed 3 times with NH4Cl-solution (27percent), KHCO3-solution (25percent) and NaCl-solution (26percent). Active charcoal is added, and the suspension is warmed to reflux for at least 1 h. Charcoal is filtered off and subsequently 800 ml t-Butylmethylether (t-BME) is added within 30 min at reflux. The mixture is cooled to 35-40° C. (precipitation of the product) and stirred for at least 1 h at 35-40° C. The suspension is cooled to 0-5° C., stirred for at least 1 additional hour and subsequently filtered off and dried in vacuo. The crude product (Irinotecan free base) is crystallized from 2-methoxyethanol. Yield: 32.9 g (88percent of theory) Appearance: yellow, crystalline powder
63.5% With sodium hydrogencarbonate; In pyridine; chloroform; EXAMPLE 28 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin 7-Ethyl-10-hydroxycamptothecin (790 mg, 2.01 mmol) and 1-chlorocarbonyl-4-piperidinopiperidine (910 mg, 3.95 mmol) were dissolved in anhydrous pyridine (50 ml), and the mixture was stirred for 1 hour at room temperature. The reaction mixture was evaporated to dryness in vacuo and the residue was dissolved in CHCl3 (200 ml). The solution was washed successively with a 7percent aqueous solution of NaHCO3 (200 ml), a saturated aqueous solution NaCl, and the CHCl3 layer was dried with MgSO4, filtered, and evaporated in vacuo. The residual material was decolorized by passing it through a short silica gel column whereby 1.11 g (94.8percent in yield) of the title compound was obtained as a pale yellow mass, which was recrystallized from ethanol (ca. 60 ml) to give colorless needles (750 mg, 63.5percent in yield).
63.5% With pyridine; at 20℃; for 1h; 790 mg (2.01 mmol) of 7-ethyl-10-hydroxycamptothecin (SN-38)And 910 mg (3.9 5 mmol) of 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride,Was mixed with anhydrous pyridine (50 mL).The dissolved mixture was stirred at ambient temperature for 1 hour.The mixture was concentrated under reduced pressure.The concentrated residue was dried under reduced pressure.The dried residue was dissolved in chloroform (200 mL).The dissolved solution was washed successively with 7percent sodium bicarbonate (NaHCO 3) (200 mL) and saturated brine,Dry over sodium sulfate,And concentrated using a vacuum condenser.After concentration,The product was refined by liquid chromatography,Recrystallization with ethanol (60 mL) gave 750 mg (yield: 63.5percent) of the title compound.
The compound 4 was dissolved in pyridine and reacted with 4-piperidinopiperidinecarbamyl chloride dissolved in DCM. The DCM and pyridine are removed by distillation and the crude mixture was worked up by dissolving the crude mixture in DCM and treating with saturated aqueous sodium bicarbonate solution, collecting the organic phase and purifying using column chromatography to afford pure compound 2.
With pyridine; at 40℃; for 2h;Product distribution / selectivity; EXAMPLE 4 Preparation of Irinotecan 4-piperidinopiperidine carbamoyl chloride obtained from Example 3 was dissolved in 3.24 L of pyridine, followed by the addition of 54 g (0.137 moles) of 7-ethyl 10-hydroxy camptothecin, prepared according to Example 2. The mixture was heated to 40° C. with simultaneous stirring for 2 hours under a nitrogen atmosphere. The reaction mixture was cooled to about 27° C.; then filtered through a celite bed and the celite was washed with 200 ml of pyridine. The filtrate was concentrated to get 250 ml solvent remaining at 50° C. under a vacuum of 650 mm Hg. The obtained residue was dissolved in 1 L of water and filtered through celite. The obtained filtrate was washed with 500 ml of n-heptane and with 2*500 ml of ethyl acetate. The aqueous layer was concentrated at 50° C. to a 250 ml volume remained and then codistilled with 2*1 L of isopropyl alcohol at 50° C. to get 500 ml solvent remaining. The obtained suspension was allowed to cool to room temperature and then filtered. The filtered solid was washed with 100 ml of isopropyl alcohol and finally subjected to drying at 70° C. for 3 hours under a vacuum of 650 mm Hg to afford 69.6 g of crude irinotecan. Purity: 94.7percent by HPLC. EXAMPLE 5; Preparation of Irinotecan; 18 g of 4-piperidinopiperidine carbamoyl chloride, obtained according to Example 3, was dissolved in 637 ml of pyridine, followed by the addition of 10 g of 7-ethyl 10-hydroxy camptothecin, prepared according to Example 2. The mixture was heated to 40° C. with simultaneous stirring for 2 hours under a nitrogen atmosphere. The above reaction mixture was cooled to about 27° C., and then filtered through a celite bed. The filtrate was concentrated at 50° C. under a vacuum of 650 mm Hg to a volume of 40 ml. 185 ml of n-heptane was added to the residue and concentrated at 50° C. under vacuum of 580 mm Hg to a volume of 50 ml. The above step was repeated two more times and then 185 ml of water was charged to the resultant residue. Adjusted the pH of the reaction mixture to 5.7 with 1 ml of acetic acid and then separated the two layers, and washed the aqueous layer with 2.x.92.5 ml of ethyl acetate. The obtained aqueous layer was concentrated at 45° C. under a vacuum of 590 mm Hg to a volume of 50 ml. 185 ml of isopropyl alcohol was charged to the residue and concentrated to a volume of 50 ml. Again 185 ml of isopropyl alcohol was charged to the above obtained residue and concentrated at 45° C. under a vacuum of 580 mm Hg to a volume of 50 ml. The suspension was cooled to 27° C. and stirred for 1 hour. The obtained suspension was filtered and washed with 20 ml of isopropyl alcohol and the solid dried at 65° C. under a vacuum of 580 mm Hg for 4 hours to afford 11.5 g of the title compound. Purity: 96.47percent by HPLC.
With pyridine; for 6 - 12h; Example - 5; Preparation of Irinotecan (IRT-5); Dissolving 7-ethyl-10-hydroxycamptothecin (50g) obtained in example 4(c) in pyridine (200 ml) under stirring at room temperature. Adding to it a solution of 1-chlorocarbonyl-4-piperidino-piperidine base (90g) in pyridine (2000 ml) and stirring for further 6 hours to 12 hours. Distilling off pyridine completely under vacuum at a temperature preferably below 45°C, cool the residue to room temperature, dissolving in chloroform (2500 ml), washing the chloroform solution with an aqueous sodium bicarbonate, followed by water. Separating chloroform layer, removing chloroform completely under vacuum, adding n-hexane filtering, drying the solid, purifying by column chromatography to obtain purified Irinotecan (IRT-5, 30g)

  • 2
  • [ 103816-19-9 ]
  • [ 97682-44-5 ]
  • [ 1310903-47-9 ]
YieldReaction ConditionsOperation in experiment
With pyridine; acetamide; triethylamine; In dichloromethane; at 30 - 35℃; for 48h; Example 6(S)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-4,9-diyl bis([1,4'-bipiperidine]-1'-carboxylate)Compound of Formula-XCharged 1 gm (1.7 mmol) of Irinotecan free base, 10 mL of MDC, 3 ml of pyridine and 150 mg of Acetamide in a flask. Prepared a solution of 0.56 gm (2.27 mmol) [1,4']bipiperidinyl-1'-carbonyl chloride (II) in 15 mL of MDC and 1 mL of TEA in another flask and added in above reaction mass. The temperature of reaction mass was raised to 30-35° C. and maintained for 48 hrs. The reaction mass was washed with 5 mL of 5percent NaHCO3 and evaporated in vacuum. To the reaction mass toluene was added and again evaporated completely. Added 10 mL of n-Hexane and stirred for 30 min, filtered and washed with n-Hexane to get the product which was purified by column chromatography by eluting with MDC:Methanol (95:5percent) to afford 208 mg of title compound having 99percent purity by HPLC.M.P.=227° C.
With pyridine; triethylamine; In acetamide; dichloromethane; at 30 - 35℃; Example 6 (S)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-4,9-diyl bis([1,4'-bipiperidine]-1'-carboxylate) [Compound of formula-X] Charged 1 gm (1.7 mmol) of Irinotecan free base, 10 mL of MDC, 3 ml of pyridine and 150 mg of Acetamide in a flask. Prepared a solution of 0.56gm (2.27 mmol) [1,4']bipiperidinyl-1'-carbonyl chloride (II) in 15 mL of MDC and 1 mL of TEA in another flask and added in above reaction mass. The temperature of reaction mass was raised to 30-35°C and maintained for 48 hrs. The reaction mass was washed with 5 mL of 5percent NaHCO3 and evaporated in vacuum. To the reaction mass toluene was added and again evaporated completely. Added 10 mL of n-Hexane and stirred for 30 min, filtered and washed with n-Hexane to get the product which was purified by column chromatography by eluting with MDC:Methanol (95:5percent) to afford 208 mg of title compound having 99 percent purity by HPLC. M.P. =227 °C
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 103816-19-9 ]

Chlorides

Chemical Structure| 143254-82-4

A120028 [143254-82-4]

1-Chlorocarbonyl-4-piperidinopiperidine hydrochloride

Similarity: 1.00

Chemical Structure| 42252-34-6

A435817 [42252-34-6]

N-Ethyl-N-methylcarbamoyl Chloride

Similarity: 0.69

Chemical Structure| 1440-60-4

A163933 [1440-60-4]

2-Chloro-1-(piperidin-1-yl)ethanone

Similarity: 0.62

Chemical Structure| 207852-63-9

A269408 [207852-63-9]

1-(4-Chloropiperidin-1-yl)ethanone

Similarity: 0.58

Chemical Structure| 207557-35-5

A166291 [207557-35-5]

(S)-1-(2-Chloroacetyl)pyrrolidine-2-carbonitrile

Similarity: 0.54

Amides

Chemical Structure| 143254-82-4

A120028 [143254-82-4]

1-Chlorocarbonyl-4-piperidinopiperidine hydrochloride

Similarity: 1.00

Chemical Structure| 71879-46-4

A145263 [71879-46-4]

1-(4-(Methylamino)piperidin-1-yl)ethanone hydrochloride

Similarity: 0.71

Chemical Structure| 42252-34-6

A435817 [42252-34-6]

N-Ethyl-N-methylcarbamoyl Chloride

Similarity: 0.69

Chemical Structure| 214147-48-5

A188396 [214147-48-5]

1-(4-Aminopiperidin-1-yl)ethanone hydrochloride

Similarity: 0.68

Chemical Structure| 160357-94-8

A984171 [160357-94-8]

1-Acetyl-4-aminopiperidine

Similarity: 0.66

Acyl Chlorides

Chemical Structure| 143254-82-4

A120028 [143254-82-4]

1-Chlorocarbonyl-4-piperidinopiperidine hydrochloride

Similarity: 1.00

Chemical Structure| 42252-34-6

A435817 [42252-34-6]

N-Ethyl-N-methylcarbamoyl Chloride

Similarity: 0.69

Related Parent Nucleus of
[ 103816-19-9 ]

Piperidines

Chemical Structure| 143254-82-4

A120028 [143254-82-4]

1-Chlorocarbonyl-4-piperidinopiperidine hydrochloride

Similarity: 1.00

Chemical Structure| 71879-46-4

A145263 [71879-46-4]

1-(4-(Methylamino)piperidin-1-yl)ethanone hydrochloride

Similarity: 0.71

Chemical Structure| 124172-53-8

A124269 [124172-53-8]

N,N'-(Hexane-1,6-diyl)bis(N-(2,2,6,6-tetramethylpiperidin-4-yl)formamide)

Similarity: 0.68

Chemical Structure| 214147-48-5

A188396 [214147-48-5]

1-(4-Aminopiperidin-1-yl)ethanone hydrochloride

Similarity: 0.68

Chemical Structure| 160357-94-8

A984171 [160357-94-8]

1-Acetyl-4-aminopiperidine

Similarity: 0.66